This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
Hang on a second…

This CME Activity has expired and is no longer available for credit.

New and Emerging Options in Osteoporosis: Improving Strategies and Outcomes in Practice

New and Emerging Options in Osteoporosis: Improving Strategies and Outcomes in Practice

Format

Webcast

Time to Complete

2.50 hours

Released

July 16, 2018

Expires

July 16, 2019
Add to Queue


Maximum Credits

2.50 / AMA PRA Category 1 Credit(s)TM
2.50 / ABIM MOC Points

An important note about ABIM MOC Part II points
Successful completion of this CME activity enables eligible participants to earn up to 2.50 ABIM-Part II Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. To claim MOC points, follow these easy steps:

Step 1: Complete all 3 questions under the "ABIM Part 2 Credit Questions" section, located at the bottom of the course evaluation form. This includes 1) attesting that our partner may submit your credits to ABIM, 2) attesting that you are ABIM board certified, 3) providing your ABIM #, and 4) providing your date of birth (MM/DD).

Step 2: Our partner, Endocrine Society, will send your MOC points to your ABIM account within 1 month.

Please check your ABIM account to check the status of your MOC points. If you have any questions about your MOC points, please contact education.endocrine.org/contact.

Accredited Provider



Provided by the Endocrine Society

Commercial Supporter

This activity is supported by an educational grant from Amgen Inc.

Program Description

In this CME and MOC accredited educational program, groundbreaking thought-leaders John P. Bilezikian, MD, PhD (hon); Richard Eastell, MD, FRCP, FRCPath, FMedSci; Bart L. Clarke, MD; and Benjamin Zev Leder, MD, will discuss the new and emerging options in osteoporosis. The program discusses the current state of osteoporosis treatment, antiresorptive and antibody-based therapy, parathyroid hormone analogues as therapeutic agents, and sequential and combination therapy with anabolic and antiresorptive agents. The program includes numerous audience case-based questions and concludes with a panel discussion with additional questions and answers to increase your understanding of the new and emerging options in osteoporosis.

Intended Audience

This activity is intended for endocrinologists and endocrine fellows, primary care physicians, physician assistants, nurse practitioners, and other healthcare professionals.

Educational Objectives

Upon completion of this educational activity, learners will be better able to:

  • Describe existing clinical challenges in the diagnosis and management of osteoporosis and identify common barriers in management
  • Apply current guidelines and state of care methods when assessing and treating patients at risk for low trauma fractures or living with osteoporosis
  • Interpret the mechanism of action, benefits, and limitations of emerging osteoporosis therapies, and recognize the potential impact of current trials on practice

Conflict Of Interest Disclosure Policy

STATEMENT OF INDEPENDENCE
As a provider of continuing medical education (CME) accredited by the Accreditation Council for Continuing Medical Education, the Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of the Endocrine Society's Special Programs Committee (SPC). The commercial supporter(s) of this activity have no influence over the planning of this CME activity.

DISCLOSURE POLICY
The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.

The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

Faculty

John P. Bilezikian, MD, PhD (hon) – Program Chair
Dorothy L. and Daniel H. Silberberg Professor of Medicine
Vice Chair, International Education and Research
Chief, Emeritus, Division of Endocrinology
College of Physicians and Surgeons, Columbia University
New York, NY

Dr. Bilezikian has disclosed the following:
Advisor Group: Amgen Inc., Radius, Shire, Ultragenyx
Ad Hoc Consultant: Lilly USA, LLC

Richard Eastell, MD, FRCP, FRCPath, FMedSci
Professor of Bone Metabolism
Head of the Academic Unit of Bone Metabolism
Director of the Mellanby Centre for Bone Research
University of Sheffield
Metabolic Bone Centre
Northern General Hospital
Sheffield, United Kingdom

Dr. Eastell has disclosed the following:
Consulting Fee: Alexion Pharmaceuticals, Inc., Amgen Inc.
Grant Recipient: Alexion Pharmaceuticals, Inc., Amgen Inc., Immunodiagnostic Systems

Bart L. Clarke, MD
Professor of Medicine
Mayo Clinic
Rochester, MN

Dr. Clarke has disclosed the following:
Consultant: Amgen Inc., Bristol-Myers Squibb
Research Support: Shire

Benjamin Zev Leder, MD
Department of Medicine
Harvard Medical School
Endocrine Unit
Massachusetts General Hospital
Boston, MA

Dr. Leder has disclosed the following:
Advisory Board Member: Amgen Inc., Radius Health, Inc.
Grant Recipient: Amgen Inc., Lilly USA, LLC

Accredited Provider Disclosure

Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships.

Publishing Staff Disclosures

The following SPC member who planned and reviewed content for this activity reported relevant financial relationship(s):

Natalie Cusano, MD, has disclosed the following:
Research Support: Shire
Speaker: Shire

The following SPC members reported relevant financial relationships:
Zahid Ahmad, MD, has disclosed the following:
Research Support: Regeneron, FH Foundation
Consultant: Regeneron
Speaker: Amgen Inc., Genzyme, Sanofi

Andrew Ahmann, MD, has disclosed the following:
Research Support: DexCom, Lexicon, Medtronic, Novo Nordisk
Consultant: Dexcom, Novo Nordisk, Trividia Health

Giuseppe Barbesino, MD, has disclosed the following:
Spouse: Employee of Genzyme

John Carmichael, MD, has disclosed the following:
Research Support: Novo Nordisk, Chiasma, Novartis, Pfizer, Strongbridge Biopharma; Speaker: Novartis
Advisory Board: Pfizer, Chiasma, Ionis Pharmaceuticals

Natalie Cusano, MD, has disclosed the following:
Research Support: Shire
Speaker: Shire

Joan Han, MD, has disclosed the following:
Research Support: Rhythm Pharmaceutical

Steven T. Harris, MD, has disclosed the following:
Ad hoc consultant on Advisory Boards: Eli Lilly & Company, Merck, Radius Health
Speaker: Amgen Inc., Eli Lilly & Company, Radius Health, Shire

Alan Kelly, MD, has disclosed the following:
Speaker: Eli Lilly

Jonathan Purnell, MD, has disclosed the following:
Advisor: Novo Nordisk

Neda Rasouli, MD, has disclosed the following:
Research Support: AstraZeneca/Amylin, Boehringer Ingelheim, Bristol Meyer Squibb, Calibra, GlaxoSmithKline, INTARCIA Therapeutics, Ionis Pharmaceuticals, Novo Nordisk

The Endocrine Society has reviewed these relationships to determine which are relevant to the content of this activity and resolved any identified conflicts of interest for these individuals.

The following SPC members reported no relevant financial relationships:
Amy Rothberg, MD
Susmeeta Sharma, MD

Credit

2.50

Type

AMA PRA Category 1 Credit(s)TM

Accreditation Statement

The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Endocrine Society has achieved Accreditation with Commendation.

Designation Statement

The Endocrine Society designates this enduring activity for a maximum of 2.50 AMA PRA Category 1 CreditsTM  and 2.50 ABIM MOC Points. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

To receive a maximum of 2.50 AMA PRA Category 1 CreditsTM  and 2.50 ABIM MOC Points, participants must complete the activity evaluation by June 30, 2019.

ABIM MOC Part II Point

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2.50 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity

Disclosure of Unlabeled Use

The Endocrine Society has determined that disclosure of unlabeled/off-label or investigational use of commercial product(s) is informative for audiences and therefore requires this information to be disclosed to the learners at the beginning of the presentation. Uses of specific therapeutic agents, devices, and other products discussed in this educational activity may not be the same as those indicated in product labeling approved by the Food and Drug Administration (FDA). The Endocrine Society requires that any discussions of such “off-label” use be based on scientific research that conforms to generally accepted standards of experimental design, data collection, and data analysis. Before recommending or prescribing any therapeutic agent or device, learners should review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse events.

Disclaimer

The information presented in this activity represents the opinion of the faculty and is not necessarily the official position of the Endocrine Society.

Use of professional judgment
The educational content in this activity relates to basic principles of diagnosis and therapy and does not substitute for individual patient assessment based on the health care provider’s examination of the patient and consideration of laboratory data and other factors unique to the patient. Standards in medicine change as new data become available.

Drugs and dosages
When prescribing medications, the physician is advised to check the product information sheet accompanying each drug to verify conditions of use and to identify any changes in drug dosage schedule or contraindications.

Instructions

To obtain credit, a score of 70% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.

For questions about content or obtaining CME credit, please contact the Endocrine Society at education.endocrine.org/contact.

SYSTEM REQUIREMENTS

Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue